menu
    • menu

    Company profile for Liminatus Pharma

    NEW Drugs in Dev: 2
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    The focus behind the incorporation of our company is to develop (from clinical trials and FDA approvals through to manufacturing and sales) solid tumor cancer CAR-Ts that treat metastatic GI cancers by using GCC CAR-T therapies. To achieve this goal, we have obtained a license for all GCC CAR-T-related patents and know-hows from Targeted Diagnostics & Therapeutics, Inc. (TDT), and our merger with Viral Gene, Inc., a company...
    The focus behind the incorporation of our company is to develop (from clinical trials and FDA approvals through to manufacturing and sales) solid tumor cancer CAR-Ts that treat metastatic GI cancers by using GCC CAR-T therapies. To achieve this goal, we have obtained a license for all GCC CAR-T-related patents and know-hows from Targeted Diagnostics & Therapeutics, Inc. (TDT), and our merger with Viral Gene, Inc., a company that develops virus-based cancer immunotherapeutics, will help position us as a leader in GCC CAR-T therapeutics.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Liminatus PharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    6 Centerpointe Drive Suite 625 La Palma, CA 90623
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.liminatuspharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Liminatus Pharma Announces Phase 1 Trial of IBA101, CD47 Antibody
    Liminatus Pharma Announces Phase 1 Trial of IBA101, CD47 Antibody

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257130/0/en/Liminatus-Pharma-Announces-Planned-Phase-1-Clinical-Trial-of-IBA101-a-Next-Generation-CD47-Blocking-Antibody.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Liminatus Announces Pricing of $4.0 Million Public Offering
    Liminatus Announces Pricing of $4.0 Million Public Offering

    17 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/17/3239319/0/en/Liminatus-Pharma-Inc-Announces-Pricing-of-4-0-Million-Public-Offering.html

    GLOBENEWSWIRE
    17 Feb 2026
    Share Share
    Liminatus Pharma Inks $30M Equity Deal With Capital Trust Group
    Liminatus Pharma Inks $30M Equity Deal With Capital Trust Group

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3177589/0/en/Liminatus-Pharma-Inc-NASDAQ-LIMN-Signs-MOU-with-Capital-Trust-Group-for-USD-30-Million-Equity-Investment-via-an-earn-out-mechanism-and-Future-Strategic-Cooperation.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    Liminatus to Launch Subsidiary for $500M BNB Crypto Investment
    Liminatus to Launch Subsidiary for $500M BNB Crypto Investment

    28 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/28/3122367/0/en/Liminatus-Pharma-Inc-to-Launch-American-BNB-Strategy-Subsidiary-and-Target-Up-To-500-Million-Fund-for-BNB-Investment-as-Part-of-Crypto-Market-Initiative.html

    GLOBENEWSWIRE
    28 Jul 2025
    Share Share
    Liminatus Eyes $500M Digital Asset Investment Plan
    Liminatus Eyes $500M Digital Asset Investment Plan

    25 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/25/3121787/0/en/Liminatus-Pharma-Inc-Evaluates-Formation-of-Digital-Asset-Investment-Vehicle-Targeting-Up-To-500-Million-in-Capital-Strategies.html

    GLOBENEWSWIRE
    25 Jul 2025
    Share Share
    Liminatus Pharma Advances Digital Asset-Linked Capital Strategy
    Liminatus Pharma Advances Digital Asset-Linked Capital Strategy

    24 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/24/3121080/0/en/Liminatus-Pharma-Inc-Takes-Next-Step-in-Evaluating-Digital-Asset-Linked-Capital-Strategy.html

    GLOBENEWSWIRE
    24 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search